| Literature DB >> 29849733 |
Chunhua Zhou1, Yingyi Luo1, Zhouxi Lei1, Gang Wei1.
Abstract
Dendrobium denneaum paxt., which has been widely used for health prevention in traditional Chinese medicine (TCM), is one of the most popular tonic herbs in China. In order to analyze its flavonoids, characterization and antitumor activity of crude extract and flavonoids rich fractions from D. denneaum paxt. were investigated. Flavonoids extracted from D. denneaum paxt. were clearly enriched in fraction II after determining the total flavonoids content; there were 15 characteristic peaks which have been detected; ultra-high performance liquid chromatography-electrospray ionization/mass spectrometry (UHPLC-ESI-MS/MS) was applied for structural elucidation of compounds. 13 characteristic peaks including flavonoid-O-glycosides and flavonoid-C-glycosides were determined or preliminarily characterized through comparing retention times and UV and MS spectra with standard compounds or documented literature. The antitumor activity of fraction II on human liver cancer cells HepG2 was investigated. MTT assay method was used to test the antiproliferation activity and to confirm the appropriate treatment concentration as well as inducing time. The morphological changes of the apoptosis cells after being induced by fraction II were observed by a Hoechst reagent and the apoptosis rate was tested by flow cytometry. The results showed that fraction II can inhibit HepG2 cells from proliferation in a dose-dependent and time-dependent manner. The apoptosis experiments indicated that fraction II can significantly induce apoptosis in HepG2 cells in a concentration over 50 μg/mL for 48 h and the most effective level was 150 μg/mL for 48 h.Entities:
Year: 2018 PMID: 29849733 PMCID: PMC5937514 DOI: 10.1155/2018/8936307
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The UHPLC-ESI/MS (TIC) fingerprint of Dendrobium aurantiacum var. denneaum. Apigenin-6,8-di-C-β-D-glucoside (3), Apigenin-6-c-β-D-xyloside-8-C-β-D-glucoside (4), Isoschaftoside (5), Schaftoside (6), Quercetin-3-O-rutinoside-7-O-glucoside (7), Apigenin-6-C-β-D-glucoside-8-c-β-D-xyloside (8), Apigenin-6-C-glucosyl-2′′-O-xyloside (9), Apigenin-8-C-glucosyl-2′′-O-xyloside (10), Quercetin-7-O-rutinoside (11), Rutin (12), Kaempferol-3-O-rutinoside (13), Kaempferol-7-O-rutinoside (14), Apigenin-7-O-rutinoside (15).
MS date for characterization of compounds in Dendrobium denneaum paxt. by UHPLC-ESI-MS/MS.
| Peak number | RT (min) | RRT | Negative ions ( | MSn | Identification |
|---|---|---|---|---|---|
| (3) | 9.5 | 0.24 | 593 [M-H]– | MS2: 503.19, 473.01 (100), 383.11, 353.09 | Apigenin-6,8-di-c- |
| (4) | 11.98 | 0.28 | 563 [M-H]– | MS2: 503.08, 473.04 (100), 443.08, 383.10, 353.07 | Apigenin-6-C- |
| (5) | 14.53 | 0.26 | 563 [M-H]– | MS2: 503.07, 473.03 (100), 443.10, 383.06, 353.05 | Isoschaftoside |
| (6) | 15.2 | 0.17 | 563 [M-H]– | MS2: 473.07, 443.10 (100), 383.10, 353.09 | Schaftoside |
| (7) | 17.58 | 0.09 | 771 [M-H]– | MS2: 609.22 (100), 462.98; MS3: 301.06 | Quercetin-3-O-rutinoside-7-O-glucoside |
| (8) | 19.57 | 0.26 | 563 [M-H]– | MS2: 473.09, 443.10 (100), 383.18, 353.12 | Apigenin-6-C- |
| (9) | 21.6 | 1 | 563 [M-H]– | MS2: 413.04 (100), 293.06; MS3: 293.08 | Apigenin-6-C-glucosyl-2′′-O-xyloside |
| (10) | 24.05 | 1.09 | 563 [M-H]– | MS2: 413.04 (100), 293.10 | Apigenin-8-C-glucosyl-2′′-O-xyloside |
| (11) | 25.95 | 0.5 | 609 [M-H]– | MS2: 300.02 (100), 271.06 MS3: 271.03, 255.05, 179.00, 150.94 | Quercetin-7-O-rutinoside |
| (12) | 28.05 | 2.02 | 609 [M-H]– | MS2: 301.04 (100), 271.09; MS3: 271.07, 255.08, 179.00, 151.01 | Rutin |
| (13) | 33.13 | 0.13 | 593 [M-H]– | MS2: 285.0 | Kaempferol-3-O-rutinoside |
| (14) | 38.86 | 0.39 | 593 [M-H]– | MS2: 285.07 | Kaempferol-7-O-rutinoside |
| (15) | 42.05 | 0.13 | 577 [M-H]– | MS2: 269.18 (100), 225.07 | Apigenin-7-O-rutinoside |
Figure 2Chemical structures and MS/MS spectra of 8 flavonoids, Apigenin-6,8-di-C-β-glucoside (a), Isoschaftoside (b), Schaftoside (c), Quercetin-3-O-rutinoside-7-O-glucoside (d), Rutin (e), Kaempferol-3-O-rutinoside (f), Apigenin-7-O-rutinoside (g), Apigenin-6-C-glucosyl-2′′-O-xyloside (h).
Figure 3Effect of fraction II on the inhibition of HepG2 cell growth. Measurement of the effect of fraction II on the cytotoxicity in HepG2 cells using MTT assay. The vertical axis showed the cell viability culture with different corresponding concentration of the fraction II on horizontal axis. The lines of ● and ▲ represented incubation time of 24 h and 48 h. The cell viability was decreased dose- and time-dependently following incubation with 10, 25, 50, 100, and 150 μg/mL fraction II for 24 h and 48 h. The concentration of 5-Flu was 50 μg/mL as the positive drug group. P < 0.01 compared to the control group (0 μM fraction II).
Figure 4Effect of fraction II on the morphological changes in HepG2 cells using fluorescence microscopy. Nuclear staining with Hoechst 33258 using fluorescence microscopy showed that fraction II induces typical cell apoptosis including membrane blebbing, cytoplasm shrinkage, nuclear chromatin condensation, and nucleoli fragmentation.
Figure 5(a) Effect of fraction II on cell apoptosis in HepG2 cells. (b) HepG2 cells were treated with 0, 50, and 150 μg/mL of fraction II for 48 h and the percentage of apoptotic cells was determined using Annexin V-FITC and PI. The concentration of 5-Flu was 50 μg/mL as the positive drug group. P < 0.01 compared with the control group (0 μM fraction II).